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Available online 28 April 2016Purpose: To compare the effects of nine months of exercise training and ibuprofen supplementation (given
immeditately after exercise sessions) on bone and muscle in postmenopausal women.
Methods: In a double-blind randomized trial, participants (females: n = 90, mean age 64.8, SD 4.3 years) were
assigned (computer generated, double blind) to receive supervised resistance training or stretching 3 days/
week, and ibuprofen (400 mg, post-exercise) or placebo (i.e. 4 groups) for 9 months. In this proof-of-concept
study the sample size was halved from required 200 identiﬁed via 90% power calculation. Baseline and post-
intervention testing included: Dual energy x-ray absorptiometry (DXA) for lumbar spine, femoral neck, and
total body areal bone mineral density (aBMD); geometry of proximal femur; total body lean tissue and fat
mass; predicted 1-repetition maximummuscle strength testing (1RM; biceps curl, hack squat).
Results: Exercise training or ibuprofen supplementation had no effects on aBMD of the lumbar spine, femoral
neck, and total body. Therewas a signiﬁcant exercise × supplement × time interaction for aBMD ofWard's region
of the femoral neck (p= 0.015)with post hoc comparison showing a 6% decrease for stretchingwith placebo vs.
a 3% increase for stretchingwith ibuprofen (p= 0.017). Resistance training increased biceps curl and hack squat
strength vs. stretching (22% vs. 4% and 114% vs. 12%, respectively) (p b 0.01) and decreased percent body fat com-
pared to stretching (2% vs. 0%) (p b 0.05).
Conclusions: Ibuprofen supplementation provided some beneﬁts to bone when taken independent of exercise
training in postmenopausal women. This study provides evidence towards a novel, easily accessible stimulus
for enhancing bone health [i.e. ibuprofen].






Inﬂammation is considered a main pathophysiological contributor
to sarcopenia (i.e., loss of muscle mass and muscle function) (J Am
Med Dir Assoc, 2011) and osteoporosis (i.e., loss of bone mass and
bone strength) (Med Sci Sports Exerc, 2009). Sarcopenia and osteoporo-
sis are associated with frailty and functional impairment, resulting in
the decreased capacity to perform daily living activities, ultimately
impacting on quality of life and increasing mortality (J Am Med DirPhysical Activity Complex, 87
).
. This is an open access article underAssoc, 2011; De Martinis et al., 2006). Resistance training is an effective
intervention for increasingmuscle and bonemass; however, aging indi-
viduals experience an attenuated response to resistance training which
contributes to aging anabolic resistance and sarcopenia (Breen and
Philips, 2011). Furthermore, the increase in areal bone mineral density
(aBMD) at clinically relevant sites such as the lumbar spine and femoral
neckwith resistance training are modest (~1–2%) but nonetheless ben-
eﬁcial (Gomez-Cabello et al., 2012; Kohrt et al., 2013). Therefore, a
longer-term (i.e. N6 months) resistance training program combined
with additional interventions may be required to produce signiﬁcant
muscle and/or bone beneﬁts in aging adults.
Ibuprofen is a non-steroidal anti-inﬂammatory drug (NSAID) known
for its anti-inﬂammatory properties via reductions of prostanoids derivedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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zymes (Rainsford, 2009). Ibuprofen supplementation attenuates the loss
of muscle mass in animal models of aging (McCarthy et al., 2004; Rieu
et al., 2009). Epidemiological studies in humans demonstrate associa-
tions between regular NSAID use and moderate (~2–6%) increases in
aBMD at clinically relevant sites (Bauer et al., 1996; Carbone et al.,
2003;Morton et al., 1998; Richards et al., 2006). A systematic review sug-
gests that the beneﬁcial effects of NSAIDs on bone health may be due to
the attenuation of inﬂammatory cytokines inhibiting bone resorption
(Konstantinidis et al., 2013). Collectively, ibuprofen may reduce inﬂam-
mation associated muscle and bone loss in aging humans.
Evidence of the combined effects of exercise and ibuprofen supple-
mentation is limited.When ibuprofen is administered following exercise
training, the inhibition of prostaglandins (PGE2) may have beneﬁcial ef-
fects on muscle and bone health via prevention of protein catabolism,
resulting in muscle accretion and protein retention in older adults
(Trappe et al., 2011); and inhibition of the altered inﬂammatory re-
sponse of COX-2 and prostaglandin E2 (PGE2) after the mechanically in-
duced bone formation has already occurred (Kohrt et al., 2013; Kohrt
et al., 2010). A high dose of ibuprofen (1200 mg daily) is effective for in-
creasing muscle size and strength in older adults over a short resistance
training period (12 weeks) (Trappe et al., 2011). A lower dose of ibupro-
fen (400 mg) administered only after resistance training (3–5 days/
week) over a shorter training period was not effective in increasing
lean tissue mass or muscle strength in younger individuals or older
women (Candow et al., 2013; Krentz et al., 2008); however, it was effec-
tive for increasing the aBMD of clinically relevant sites in premenopausal
women during a longer training period (9 months) (Kohrt et al., 2010).
While ibuprofen given after resistance training appears beneﬁcial for
bone in premenopausal women, this was not evident in a recent study
of postmenopausal women over a similar training period (Jankowski
et al., 2015). Research over longer training periods in older women re-
mains scarce, with the only notable study lacking an exercise control
group, thus not allowing for the determination of the interaction be-
tween resistance training and ibuprofen (Jankowski et al., 2015).
Additional anti-inﬂammatory interventions combined with resis-
tance training are needed to determine if there are clinically relevant
improvements in aging muscle and bone. The purpose of our study
was to investigate the effects of a long term (9 months) intervention
of combined ibuprofen (400 mg) and exercise training on muscle and
bone in postmenopausal women (60 y or greater). We hypothesized a
combined effect of progressive resistance training and ibuprofen sup-
plementation leading to improved lean tissuemass andboneproperties.
2. Participants and methods
2.1. Study design
A proof-of-concept, double-blind (for ibuprofen), factorial random-
ized control trial design was employed to compare the independent
and combined effects of ibuprofen supplementation and exercise train-
ing. Participants were randomized 1:1:1:1 to one of four groups after
being cleared for inclusion. Randomization was completed using a
computer-generated allocation schedule with a block size of four by
one of the investigators who was not involved in the measurement of
outcomevariables or theanalysis. The four uniquegroupswere: 1) resis-
tance training combined with ibuprofen supplementation (ExIbu);
2) resistance training combined with placebo supplementation (Ex);
3) ﬂexibility training (exercise placebo) combined with ibuprofen sup-
plementation (Ibu); and 4) ﬂexibility training combined with placebo
supplementation (Control). Ibuprofen dosagewas 400mgafter exercise
training only (maximum 3 times per week) for 9months. This dose and
length of supplementation was chosen because it is safe and effective
for increasing aBMD (hip region) when taken after resistance training
in premenopausal women (Kohrt et al., 2010). Further, this dosage
was well-tolerated in a 9 week pilot study of postmenopausal womencompleted by our research group (Candow et al., 2013). Ibuprofen and
placebo (methylcellulose) were administered in a double-blind fashion
in the formof capsules thatwere identical in taste, color, and appearance.
The supplementwas pre-packaged into containers that were sequential-
ly numbered according to the randomization schedule, ofwhich the allo-
cation sequence was concealed from the research assistants enrolling
and assessing the participants. After completion of the baseline testing,
participants were provided containers with the supplement (i.e. ibupro-
fen or placebo), calcium and vitamin D (600 mg/d and 400 IU/d, respec-
tively), and an exercise/supplement tracking log. Participants in the
stretching group took their supplement at home while participants in
the resistance training group took their supplement as provided directly
by a research assistant after each resistance training session as post-
exercise ibuprofen has a beneﬁcial effect on aBMD (Kohrt et al., 2010).
Calcium and Vitamin D was taken daily at home by all participants. Al-
though participants could not be blinded to the exercise assignment,
they were blinded to the hypothesis that the resistance training would
be superior to ﬂexibility training. All the researchers involved in the out-
come assessment and analysis were blinded to the group assignment.
The personnel supervising the training programwere blinded to the sup-
plement (i.e. ibuprofen or placebo). Statistical analysis was blinded
through the coding of the groups. The study was approved by the Bio-
medical Research Ethics Board of the University of Saskatchewan.
Reporting of this study adhered to the Consolidated Standards of
Reporting Trials (CONSORT) guidelines for randomized clinical trials.
This trial was registered with clinicaltrials.gov (NCT01886196).
2.2. Participants
Postmenopausal women 60 years or older were recruited via
advertisements in local newspapers and posters from January 2013 to
September 2013. All 164 potential participants that responded to the ad-
vertisements were assessed for study eligibility by modiﬁcation of the
Mediterranean Osteoporosis Study Questionnaire (MEDOS) (Dequeker
et al., 1991). Only subsections of MEDOS important for this study were
addressed (i.e. diseases/medications applicable to bone/ibuprofen).
Grounds for exclusion included usage of medication or presentation of
disease that is known to affect bone mineral metabolism. Thus, partici-
pants with Crohn's Disease or Cushing Disease, currently taking systemic
corticosteroids, or having taken bisphosphonates, hormone replacement
therapy, selective estrogen receptor modulators, parathyroid hormone,
or calcitonin within the past 12 months were excluded. Participants
were also excluded if they were currently taking medication or had pre-
sentation of disease that is known to interfere with ibuprofen. Thus, par-
ticipantswith severe osteoarthritis or severe heartburn, ulcers, or gastritis
requiring acid reducers (e.g. H2 blockers or proton pump inhibitors), cur-
rently taking NSAID (e.g. prophylactic acetylsalicylic acid) or blood thin-
ners due to past episodes of deep vein thrombosis or pulmonary
embolism were excluded. After clearing initial exclusion criteria, partici-
pants were further evaluated for 10-year risk of fracture based on age
and femoral neck aBMD t-score (i.e. Canadian Association of Radiologists
andOsteoporosis Canada [CAROC]) and excluded if theywere classiﬁed as
“high” risk for fracture (CanMed Assoc J, 2010). The CAROCmethod clas-
siﬁes individuals as being at “low”, “moderate”, or “high risk” for fracture,
where fragility fracture or systemic corticosteroid use (i.e. a prednisone
equivalent dosage of ≥7.5 mg/day for at least three cumulative months
during the preceding year) moves the individual up one risk category
(Can Med Assoc J, 2010). Participants were instructed not to ingest any
type of NSAID for the duration of the study. Finally, participants were ex-
cluded if theywere active smokers orwere currently takingpart in amod-
erate to vigorous resistance-training program more than once per week.
After applying the exclusion criteria, 144 women were eligible and
90 decided to participate in the study (see Fig. 1 for ﬂowdiagramof par-
ticipants). To detect clinically relevant differences in primary variables
with 90% power (2 sided, p ≤ 0.05), and accommodate 20% attrition,
each group would require approximately 50 per-protocol participants
Fig. 1. CONSORT Flow diagram. Participant ﬂow throughout duration of study.
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study the target sample size identiﬁed via power calculations was
halved. Further justiﬁcation for the sample size of this proof-of-
concept study was based on a previous intervention of young individ-
uals (n = 54) with beneﬁcial aBMD response to NSAID supplementa-
tion after exercise (Kohrt et al., 2010) and increased because older
individuals have greater variability in their physiologicalmeasurements
(Candow and Chilibeck, 2005). Participants were randomized into 4
groups, as described in the study design (Fig. 1).
Participants signed informed consents and completed the Physical
Activity Readiness Questionnaire (PAR-Q) (Thomas et al., 1992) prior
to baseline testing to ensure there was no contra-indication to exercise
participation. Those with a positive response to the PAR-Q and those
over the age of 69 years were required to have their physician complete
the Physical Activity Readiness Medical Examination (PARmedX) prior
to participation. All participants completed the intervention by July
2014.2.3. Interventions
Ibuprofen and placebo obtained from the Saskatoon Medical Arts
Pharmacy (Saskatoon, SK) were administered orally in identical cap-
sules at a dose of 400mg immediately following exercise training (resis-
tance and ﬂexibility training) 3 days per week maximum. The contents
of the ibuprofen (96% ibuprofen) were veriﬁed through independent
laboratory testing (Eagle Analytical Services, Houston, TX). The placebo
capsule contained methylcellulose that was indistinguishable in ap-
pearance from the ibuprofen. All participants received a supplement
of 600 mg of calcium and 10 μg (400 I.U.) of vitamin D per day in the
form of a pill or chew (Jamieson Laboratories, Toronto, ON) to assist in
meeting the Osteoporosis Society of Canada recommendations of
1200 mg per day for calcium and 20 μg (800 I.U.) per day for vitamin
D (Can Med Assoc J, 2010).The exercise intervention consisted of resistance training performed
3 days per week on non-consecutive days. Prior to their ﬁrst exercise
session, participants attended an orientation session in our research
gymnasium to be familiarized with the exercises and machines. Orien-
tation and all resistance training exercise sessions were completed
under the supervision of a Canadian Society for Exercise Physiology-
Certiﬁed Exercise Physiologist research assistant (www.csep.ca). The
resistance training exercise intervention required 2 sets of 8–12 repeti-
tions of 12 exercises designed to train allmajormuscle groups. Exercises
were performed on Lever machines (Pulse Fitness Systems; Winnipeg,
Manitoba, Canada) or with free weights. Exercises performed on ma-
chines included: hack squat, hip ﬂexion, extension, adduction, and ab-
duction, and dorsiﬂexion. Exercises performed with dumbbells
included: biceps curl, forearm curl, supinated wrist curl, pronated
wrist curl, front and side step ups, single leg lunge, and plantar ﬂexion.
In addition, participants performed a medicine ball toss and catch
against a wall. Participants were encouraged to work to muscle fatigue
and monitored to ensure that resistance was increased once two full
sets of 12 repetitions could be performed with good form. Participants
were required to sign in for every exercise session and providedwith re-
sistance training logs to track sets, loads, and repetitions (i.e. overall vol-
ume) and supplement tracking logs to track dosages of supplement and
calcium and vitamin D consumption.
The exercise placebo consisted of a home-based ﬂexibility program
performed 3 days per week on non-consecutive days. Flexibility partic-
ipants completed an orientation at our research gymnasium and were
providedwith a print version of the home-based program. The exercise
placebo intervention required 2 sets held for 20–30 s of full body ﬂexi-
bility (i.e. stretching) exercises. The exercise placebo groups were
contacted monthly to assess compliance to the program and monitor
adverse events. Flexibility participants were advised not to perform
any resistance training exercise for the duration of the intervention.
Compliance to the exercise intervention was assessed by attendance
at the supervised exercise sessions (Ex and ExIbu) and tracking logs
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events for all groups during the intervention were recorded on an ad-
verse event form. Compliance to the supplement and calcium and vita-
min D for all groups was assessed via tracking logs and amount of left-
over supplement. In addition, prior to being ‘unblinded’, to assess the ef-
fectiveness of the blinding, participants were questioned regarding
what supplement they thought they were on. The duration of the inter-
vention was 9 months.
2.4. Outcomes
All outcome measurements were completed at baseline and
9 months (Kohrt et al., 2010). Primary outcomes were the aBMD of
the proximal femur and lumbar spine. Secondary outcomes were:
cross-sectional area (CSA), subperiosteal width (SPW), and section
modulus (Z) of the narrow part of the femoral neck, the intertrochanter
region, and the shaft of the proximal part of the femur; total body aBMD,
lean tissue and fat mass; biceps curl and hack squat muscular strength;
and backwards tandem walking balance performance. Tertiary out-
comes were adverse events. Dual energy x-ray absorptiometry (DXA)
scans were performed prior to any physical testing to determine study
eligibility. Following the DXA scan, participants completed balance test-
ing, and then performed a standardized warm-up prior to any strength
tests. The tests were performed in this particular order to prevent bal-
ance testing being compromised due to muscle fatigue resulting from
strength testing.
2.4.1. Dual energy x-ray absorptiometry (DXA)
Areal bonemineral density and body compositionwere assessed via
DXA in arraymode (QDRDiscoveryWi; Hologic, Inc., Bedford,MD, USA)
using QDR software for Windows XP (QDR Discovery). Sites measured
included lumbar spine (L1–L4 vertebrae), proximal femur (total hip,
femoral neck, trochanter, intertrochanter, and Ward's region), and
total body. The coefﬁcients of variation for lumbar spine, proximal
femur and total body aBMD in our laboratory are 0.7%, 1.0%, and 0.5%,
respectively (Chilibeck et al., 2013). Hip Structural Analysis (HSA) was
used for assessment of CSA, SPW, and Z of the narrow neck (NN),
intertrochanter (IT) and femoral shaft (FS) regions (Beck et al., 1990).
All DXA analyses were performed by a blinded study radiologist. Bone
CSA is representative of bone mineral mass within a cross-section in
terms of the cortical equivalent surface area and indicative of bone com-
pressive strength. SPW is measured as the outer diameter of the bone
computed as the blur-corrected width of the mass proﬁle.
Section Modulus (Z) provides an estimate of bone bending strength
(Beck et al., 1990). The coefﬁcients of variation for NN, IT, and FS regions,
respectively, for our laboratory are as follows: CSA (2.6%, 2.2%, and
1.8%); SPW (5.3%, 1.8%, and 1.2%); and Z (3.5%, 3.4%, and 2.1%)
(Chilibeck et al., 2013). Body composition, including fat free mass (i.e.
lean mass), fat mass, and percent body fat, was also assessed via DXA
scan. The coefﬁcients of variation for lean mass and fat mass are 1.0%
and 3.0%, respectively (Chilibeck et al., 2013).
2.4.2. Backward tandem walk
Dynamic balance was assessed, taking into account errors made, via
a timed backward tandem (i.e. heel to toe) walk over a raised 6 m long
board (Chilibeck et al., 2013). The time to cover the distance and num-
ber of errors (i.e. number of times stepping off the board)were averaged
over two trials.
2.4.3. Submaximal prediction of 1-repetition maximum
Upper and lower body strength was assessed via the submaximal
prediction of 1-Repetition Maximum (1RM). Participants were shown
proper form and breathing prior to performing a muscle-speciﬁc
warm-up. For upper body warm-up, testers selected a load for biceps
curl that the participant could easily perform 8 repetitions with proper
form. For lower body warm-up, participants performed 8 repetitions onthe hack squatmachinewith no additional load added (i.e. weight of the
machine as warm-up weight). Testers then selected an estimated load
for upper and lower body test that the participant could perform no
more than 10 repetitions with proper form. If 10 repetitions were com-
pleted in the ﬁrst attempt, a one-minute rest period was given, and the
process was repeated with a heavier load for a second and/or third at-
tempt. If 10 repetitions were not completed in the ﬁrst attempt the
test was terminated. 1RM was predicted by ﬁnding the corresponding
percentage of load utilized for number of repetitions completed (e.g. 7
repetitions corresponds to 83%, thus if load utilized was 50 kg then pre-
dicted 1RM is 60 kg) (Baechle and Earle, 2000).
2.5. Descriptive outcomes
2.5.1. Questionnaires
Participants completed a food frequency questionnaire (FFQ) and
leisure time exercise questionnaire (LTEQ) (Godin and Shephard,
1985). The validated FFQ was used to assess the changes from baseline
to post-intervention for total energy, calcium and vitamin D intakes
based on Canadian dietary reference intakes (Block 98#256318–2;
Block Dietary Data Systems, Berkeley, CA, USA). The FFQ, along with di-
rections and images showing sample portion sizes, was sent homewith
participants to complete and was checked for completeness when
returned prior to being sent for computer analysis (Nutrtion Quest,
Berkeley, CA, USA; www.nutritionquest.com). The changes in LTEQ
from baseline to post-intervention were also determined. The LTEQ as-
sesses non-work related physical activity and exercise training (i.e. car-
diorespiratory, resistance, and neuromotor) further categorized asmild,
moderate, or strenuous. In older adults the LTEQ has good reliability
(test-retest correlation of 0.62–0.74) and has been shown to have a pos-
itive association with muscular strength and power (Candow and
Chilibeck, 2005; Godin and Shephard, 1985).
2.5.2. Adverse events
Participants were asked to report any adverse events (AE) that oc-
curred throughout the duration of the study. AE forms included a brief
description of the event, onset and resolution (unless on-going) dates,
rating for seriousness and severity, and relationship to experimental
procedure.
2.6. Statistical analysis
Data were analyzed on an intent-to-treat basis using IBM SPSS Sta-
tistics for Windows (Version 21.0; Armonk, NY: IBM Corp). Baseline
characteristics of all variables were compared between groups using
Student's t-tests. Comparisons of intervention arms were analyzed via
a three-factor analysis of variance, with between-group factors for
drug (ibuprofen versus placebo) and exercise (resistance training ver-
sus ﬂexibility training [exercise placebo]) and one within-subjects fac-
tor for time (baseline versus nine months post-intervention). Tetrad
contrast hypothesis tests were used for the post-hoc analyses. We re-
port partial eta-squared (ƞp2) as estimate of effect size. All descriptive re-
sults were expressed as either means and standard deviations or mean
absolute changes and 95% conﬁdence intervals. P-values ≤ 0.05 were
deemed statistically signiﬁcant.
3. Results
Theﬁnal analysis included 69 intent-to-treat participantswith the re-
mainder lost to follow-up (Fig. 1). In comparison to drop-outs, intent-to-
treat participants had lesser fat mass (p = 0.037) and percent body fat
(p=0.004) andwere of a taller height (p=0.016). Baseline descriptives
by intervention group are presented in Table 1. Intervention groupswere
not signiﬁcantly different for any outcomes at baseline. Reported compli-
ance corresponds to both exercise and supplement as the supplement
was only consumed after exercise, and appeared similar between groups
Table 1
Baseline data by intervention group.
ExIbu Ex Ibu Control
(n = 23) (n = 22) (n = 23) (n = 22)
Age (years) 65.4 (3.5) 65.3 (4.6) 65.5 (6.7) 65.0 (4.7)
Height (cm) 160.5 (4.7) 162.4 (5.7) 162.5 (6.6) 160.0 (6.6)
Lumbar spine aBMD (g/cm2) 0.989 (0.221) 0.906 (0.093) 0.941 (0.129) 0.978 (0.184)
Total hip aBMD (g/cm2) 0.860 (0.135) 0.836 (0.080) 0.865 (0.116) 0.844 (0.144)
Femoral neck aBMD (g/cm2) 0.703 (0.126) 0.681 (0.061) 0.722 (0.105) 0.697 (0.097)
Trochanter aBMD (g/cm2) 0.654 (0.097) 0.629 (0.062) 0.669 (0.100) 0.638 (0.105)
Intertrochanter aBMD (g/cm2) 1.034 (0.167) 0.996 (0.114) 1.026 (0.147) 1.021 (0.185)
Ward's aBMD (g/cm2) 0.542 (0.134) 0.510 (0.087) 0.541 (0.099) 0.549 (0.116)
Total body aBMD (g/cm2) 1.078 (0.090) 1.034 (0.091) 1.079 (0.104) 1.074 (0.131)
Narrow neck CSA (cm2) 2.75 (0.49) 2.67 (0.22) 2.92 (0.52) 2.74 (0.35)
Narrow neck SPW (cm) 3.41 (0.33) 3.34 (0.28) 3.41 (0.30) 3.39 (0.34)
Narrow neck Z (cm3) 1.35 (0.35) 1.27 (0.18) 1.46 (0.35) 1.33 (0.19)
Intertrochanter CSA (cm2) 4.92 (0.90) 4.78 (0.59) 5.02 (0.81) 4.61 (1.04)
Intertrochanter SPW (cm) 5.53 (0.40) 5.76 (0.49) 5.81 (0.35) 5.53 (0.78)
Intertrochanter Z (cm3) 4.30 (0.93) 4.32 (0.74) 4.64 (0.88) 4.15 (1.03)
Femoral shaft CSA (cm2) 4.15 (0.65) 4.16 (0.44) 4.23 (0.67) 3.94 (0.56)
Femoral shaft SPW (cm) 3.01 (0.23) 3.01 (0.23) 3.02 (0.22) 3.01 (0.20)
Femoral shaft Z (cm3) 2.39 (0.41) 2.39 (0.31) 2.49 (0.48) 2.28 (0.47)
Total Mass (kg) 73.95 (12.91) 71.02 (11.66) 76.08 (13.73) 75.49 (14.98)
Lean mass (kg) 40.33 (5.33) 40.86 (5.13) 42.64 (5.98) 40.88 (5.11)
Fat mass (kg) 30.33 (8.14) 28.15 (7.96) 31.39 (8.88) 32.51 (10.31)
Body fat percentage (%) 42.03 (4.66) 39.07 (5.49) 40.59 (5.71) 42.15 (5.94)
Average tandem walk time (s) 52.39 (15.41) 56.00 (20.75) 52.59 (18.21) 55.49 (23.43)
Average tandem walk errors 5.11 (5.56) 3.10 (3.89) 5.29 (6.62) 3.81 (3.72)
Biceps curl 1RM (kg) 9 (1) 8 (1) 9 (2) 8 (2)
Hack squat 1RM (kg) 38 (25) 45 (30) 54 (34) 41 (20)
LTEQ score 20 (11) 20 (13) 28 (25) 21 (19)
Total energy intake 1775 (740) 1614 (485) 1726 (568) 1581 (377)
Calcium intake (mg/d) 869 (305) 787 (343) 922 (468) 729 (236)
Vitamin D intake (IU) 129(73) 142 (128) 193 (159) 155 (134)
All values are means (SD); SD = standard deviation.
Abbreviations: BMD=bonemineral density; CSA= cross-sectional area; SPW=subperiosteal width; Z= sectionmodulus; 1RM=1-repititionmaximum; LTEQ= leisure time exercise
questionnaire.
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the end of the study, the percent able to correctly identify the supple-
ment they were blindly receiving was: 1) ExIbu (n = 17): 47%, 2) Ex
(n = 19): 63%, 3) Ibu (n = 15): 47%, and 4) Control (n = 14): 79%.
The remainder either never began supplementation, guessed incorrectly,
or were unable to guess. Compliance to calcium and vitamin D supple-
mentation was similar (p N 0.05) between groups: 1) ExIbu: 83%,
2) Ex: 72%, 3) Ibu: 76%, and 4) Control: 84%. The number of participants
analyzed per outcome varied. For hip geometric properties, one (n= 1)
scan could not be analyzed for IT variables due to improper positioning.
One (n=1) intent-to-treat participant did not return for a DXA scan, but
completed other post-testing outcomes. For the balance tests, some par-
ticipants (n = 5) could not safely complete the backward tandemwalk.
For the exercise tests, some participants could not complete the biceps
curl 1RM (n = 6) or hack squat 1RM (n = 15) due to injury or refusal.
Incomplete questionnaire data for LTEQ (n = 7) and FFQ (n = 8) were
due to refusal to complete or return questionnaires.Table 2
Mean absolute changes (95% CI) from baseline to 9 months for areal bone mineral density wit
ExIbu (n = 18) Ex (n = 19) Ibu (n = 17)
Change 95% CI Change 95% CI Change 95
Lumbar spine −0.007 (−0.024, 0.009) −0.003 (−0.016, 0.010) 0.005 (−
Total hip 0.003 (−0.011, 0.018) 0.008 (−0.006, 0.022) 0.007 (−
Femoral neck −0.010 (−0.033, 0.014) −0.002 (−0.017, 0.014) −0.006 (−
Trochanter 0.001 (−0.009, 0.011) 0.004 (−0.007, 0.015) 0.006 (−
Intertrochanteric 0.007 (−0.016, 0.030) 0.010 (−0.012, 0.033) 0.005 (−
Ward's region −0.022 (−0.056, 0.012) −0.003 (−0.034, 0.029) 0.017 (−
Total body 0.005 (−0.005, 0.015) 0.002 (−0.008, 0.012) −0.003 (−
All values are mean absolute changes (95% CI) in g/cm2; CI = conﬁdence interval.
Exercise, ibuprofen, and interaction effects are presented in last two columns.
a Ibu different from Control groups (post hoc; p = 0.017).3.1. Bone properties
Group × time interactions were not signiﬁcant for the aBMD of the
lumbar spine, femoral neck, or total body (Table 2), or hip geometric
properties (Table 3). For sub-regions of the hip scans, an
exercise × supplement × time interaction was signiﬁcant for aBMD of
the Ward's area (p = 0.015; ƞp2 = 0.088). When comparing change
scores between groups, only the change score for the Ibu groupwas dif-
ferent from the Control group (p=0.017). The Control group decreased
Ward's region aBMD (Table 2).3.2. Body composition
Group × time interactions were not signiﬁcant for lean tissue
mass; however the exercise × time interaction was signiﬁcant for fat
mass (p = 0.033; ƞp2 = 0.069) and percent body fat (p = 0.019;hin groups.
Control (n = 15) Exercise Supplement Interaction
% CI Change 95% CI p-Value p-Value p-Value
0.009, 0.019) 0.011 (−0.007, 0.029) 0.069 0.482 0.883
0.007, 0.021) 0.001 (−0.012, 0.013) 0.778 0.912 0.415
0.022, 0.009) −0.023 (−0.037,−0.010) 0.285 0.600 0.148
0.008, 0.020) 0.002 (−0.006, 0.011) 0.759 0.983 0.504
0.009, 0.018) −0.006 (−0.031, 0.019) 0.369 0.719 0.511
0.006, 0.040)a −0.035 (−0.063,−0.006)a 0.786 0.261 0.015
0.013, 0.008) −0.007 (−0.015, 0.001) 0.092 0.438 0.889
Table 3
Mean absolute changes (95% CI) from baseline to 9 months for hip structural analysis within groups.
ExIbu (n = 18) Ex (n = 19) Ibu (n = 17) Control (n = 15) Exercise Supplement Interaction
Change 95% CI Change 95% CI Change 95% CI Change 95% CI p-Value p-Value p-Value
Narrow neck CSA (cm2) −0.03 (−0.15, 0.08) −0.04 (−0.13, 0.05) −0.09 (−0.20, 0.02) −0.06 (−0.12, 0.01) 0.432 0.790 0.708
Narrow neck SPW (cm) −0.04 (−0.13, 0.05) 0.10 (0.01, 0.19) 0.02 (−0.13, 0.16) 0.05 (−0.04, 0.13) 0.977 0.076 0.250
Narrow neck Z (cm3) 0.00 (−0.08, 0.09) −0.02 (−0.11, 0.07) −0.03 (−0.13, 0.06) −0.02 (−0.08, 0.05) 0.708 0.911 0.630
Intertrochanteric CSA (cm2) 0.05 (−0.08, 0.18) 0.08 (−0.13, 0.28) −0.06 (−0.23, 0.12) 0.23 (−0.31, 0.77) 0.868 0.257 0.331
Intertrochanteric SPW (cm) 0.02 (−0.09, 0.14) 0.11 (−0.02, 0.24) −0.02 (−0.22, 0.18) 0.22 (−0.21, 0.65) 0.770 0.146 0.490
Intertrochanteric Z (cm3) 0.10 (−0.08, 0.29) 0.15 (−0.15, 0.45) −0.01 (−0.25, 0.23) 0.20 (−0.24, 0.64) 0.842 0.370 0.569
Shaft CSA (cm2) 0.06 (−0.02, 0.14) −0.01 (−0.09, 0.07) −0.03 (−0.12, 0.07) 0.17 (−0.20, 0.53) 0.609 0.439 0.118
Shaft SPW (cm) −0.02 (−0.07, 0.03) −0.03 (−0.07, 0.01) −0.03 (−0.08, 0.02) 0.01 (−0.07, 0.10) 0.526 0.548 0.339
Shaft Z (cm3) 0.02 (−0.03, 0.07) −0.02 (−0.08, 0.04) −0.06 (−0.14, 0.02) 0.14 (−0.17, 0.46) 0.572 0.258 0.083
All values are mean absolute changes (95% CI); CI = conﬁdence interval.
Exercise, ibuprofen, and interaction effects are presented in last two columns.
Abbreviations: CSA = cross-sectional area; SPW= subperiosteal width; Z = section modulus; Intertroch = intertrochanter.
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fat compared to stretching (Table 4).
3.3. Strength and balance
The exercise × time interaction was signiﬁcant for hack squat
strength and biceps curl strength (p b 0.001). Resistance training in-
creased hack squat (ƞp2 = 0.456) and biceps curl (ƞp2 = 0.313) strength
compared to stretching (Table 4). Group × time interactions were not
signiﬁcant for balance (Table 4).
3.4. Diet and activity
The exercise × time interaction was signiﬁcant for total energy (p =
0.047;ƞp2=0.068) and fat intake (p=0.039;ƞp2=0.073). The stretching
group decreased total energy intake via reduced fat intake compared to
resistance training (Table 5). The exercise × time × supplement interac-
tion was signiﬁcant for vitamin D intake (p = 0.024; ƞp2 = 0.081), but
changes in vitamin D intakes did not differ between the groups in the
post-hoc analysis (Table 5). Group × time interactions were not signiﬁ-
cant for remaining macronutrients, calcium intake, or amount of leisure
time exercise performed from baseline to post-intervention (Table 5).
The recommended dietary allowances of 0.8 g/kg of protein were met
by all groups.
3.5. Adverse events
Of the 90 women randomized, two serious adverse events (SAEs)
were reported during the intervention; one in a participant assignedTable 4
Mean absolute changes (95% CI) from baseline to 9 months for body composition, balance, and
ExIbu (n = 18) Ex (n = 19) Ibu (n =
Change 95% CI Change 95% CI Change
Fat mass (kg) −1.07 (−2.01,−0.12) −0.03 (−1.08, 1.01) 0.45
Lean tissue mass (kg) 0.00 (0.00, 0.00) 0.97 (0.33, 1.66) 0.20
Body fat percentage (%) −1.21 (−2.26,−0.16) −0.54 (−1.35, 0.28) 0.20
Strength
Biceps curl (kg) 2 (1, 2) 2 (1, 3) 0
Hack squat (kg) 49 (31, 67) 40 (25, 55) 7
Dynamic balance
Average time (s) −5.21 (−11.71, 1.29) −12.47 (−22.39,-2.54) −7.86
Average errors 0.25 (−1.23, 1.73) 0.17 (−1.02, 1.35) −0.53
All values are mean absolute changes (95% CI); CI = conﬁdence interval.
Exercise, ibuprofen, and interaction effects are presented in last two columns.
Dynamic balance is average of two attempts.
a p-value for the main effect; Resistance training improved compared to stretching groups.to ExIbu and one in a participant assigned to Control. Both SAEs
were deemed as “not related” to the intervention; however, both
discontinued the intervention. The SAE in the ExIbu participant was a
transient ischemic attack (TIA). The SAE in the Control participant was
a fractured pelvis due to a fall on ice.
4. Discussion
To our knowledge, this is theﬁrst study to examine the combined ef-
fects of longer term exercise training with ibuprofen supplementation
onmuscle and bone in postmenopausalwomen using a factorial design.
Resistance training promoted greater increases in hack squat and biceps
curl strength and decreases in body fat than stretching. Contrary to our
hypothesis, augmenting resistance trainingwith ibuprofen did not have
an additive effect on bone properties or muscle mass. Exercise training
and/or ibuprofen supplementation had no effect on aBMD of the lumbar
spine (L1–L4 vertebrae), femoral neck, or total body. There was a 6% de-
crease in aBMD of Ward's region in the control group compared to a 3%
increase in the stretching and ibuprofen group, implying that ibuprofen
helpedmaintain bone density at this site. Ward's region is clinically rel-
evant as it is identiﬁed as the region at the femoral neckwith the lowest
aBMD (i.e. potentially the weakest). Collectively, these ﬁndings suggest
that ibuprofen may have some beneﬁcial bone effects for postmeno-
pausal women.
Our results add to the limited body of research investigating the ef-
fects of ibuprofen supplementation and resistance training on aging
muscle and bone biology. One notable study (Kohrt et al., 2010) demon-
strated that 400mg of ibuprofen given after resistance training sessions
over nine months improved hip aBMD (total, trochanter, femoral neckstrength.
17) Control (n = 15) Exercise Supplement Interaction
95% CI Change 95% CI p-Valuea p-Value p-Value
(−0.75, 1.65) 0.56 (−0.23, 1.35) 0.033 0.241 0.345
(−0.38, 0.78) 0.44 (−0.48, 1.36) 0.237 0.248 0.660
(−0.81, 1.21) 0.12 (−0.53, 0.77) 0.019 0.493 0.385
(0, 1) 1 (0.1) b0.001 0.248 0.455
(0, 14) 6 (−1, 12) b0.001 0.966 0.830
(−13.12,−2.61) −4.57 (−14.83, 5.70) 0.509 0.618 0.186
(−1.72, 0.66) −0.12 (−1.37, 1.14) 0.390 0.787 0.685
Table 5
Mean absolute changes (95% CI) from baseline to 9 months for descriptive outcome variables.
ExIbu (n = 18) Ex (n = 19) Ibu (n = 17) Control (n = 15) Exercise Supplement Interaction
Change 95% CI Change 95% CI Change 95% CI Change 95% CI p-Valueb p-Value p-Value
Total energy intake (kcal/d) −119 (−315, 77) 72 (−133, 276) −118 (−502, 267) −188 (−394, 18) 0.047 0.165 0.596
Total protein intake (g/d) −5 (−14, 4) −1 (−10, 8) −5 (−19, 9) −7 (−16, 3) 0.209 0.329 0.862
Total fat intake (g/d) −2 (−16, 12) 8 (−5, 20) −5 (−22, 13) −8 (−19, 2) 0.039 0.253 0.654
Total carbohydrate intake (g/d) −22 (−40,−4) −1 (−23, 21) −12 (−52, 28) −25 (−52, 1) 0.143 0.289 0.377
Calcium intake (mg/d)a −83 (−186, 19) −27 (−146, 97) −107 (−349, 134) −145 (−226,−63) 0.073 0.391 0.959
Vitamin D (μg/d)a 14 (−33, 60) −47 (−88,−7) −41 (−120, 37) −4 (−63, 55) 0.583 0.949 0.024
Leisure physical activity score
(arbitrary units)
−1 (−12, 9) 1 (−6, 7) 2 (−7, 12) 9 (−6, 25) 0.211 0.362 0.591
All values are mean absolute changes (95% CI); CI = conﬁdence interval.
Exercise, ibuprofen, and interaction effects are presented in last two columns.
a Values only include nutrients from dietary intake and do not include the supplements given during the study.
b p-value for the main effect; Stretching group decreased total energy and fat intake compared to resistance training group.
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demonstrated no signiﬁcant effect on the aBMD in older adults regard-
less of whether supplementation occurred before or after resistance ex-
ercise training (Jankowski et al., 2015). The recent data presented by
this group supports a trend for a deleterious effect of ibuprofen given
after exercise (and before) in postmenopausal women, speciﬁcally at
the hip (Jankowski et al., 2015). The authors recommended the cautious
interpretations of their ﬁndings due to the lack of an exercise control
group and drug dispensing error (Jankowski et al., 2015). Evident was
the need for further studies in humans with greater sample size and
follow-up time.
Our ﬁnding of a small beneﬁcial effect of ibuprofen on bone (Ward's
region) is supported by epidemiological studies that have found associ-
ations between regular NSAID use and improved bone density (Bauer
et al., 1996; Carbone et al., 2003; Morton et al., 1998; Richards et al.,
2006). Our study, however, showed no beneﬁt when ibuprofen was
consumed immediately after exercise sessions. An optimal intervention
might be to alter the timing of the exercise bout and ibuprofen supple-
mentation, perhaps taking ibuprofen at a time point during the day
when one is not exercising (e.g. minimum eight hours before or after)
or taking ibuprofen on non-exercise days.
Inhibition of prostaglandin synthesis by ibuprofen or other COX-
inhibitors in animal studies has produced variable results on
mechanically-loaded bone. The effect of ibuprofen may depend on the
timing of administration with regards to the mechanical stimulus. Ani-
mal experiments suggest that ibuprofen supplementation before or
during, but not after, loading impairs the bone response and adaptation
to mechanical loading (including inﬂammation mediated bone forma-
tion) (Chow et al., 1998; Li et al., 2002). Thus, while prostanoids are the-
orized to be required formechanically induced bone formation to occur,
the prostanoid-dependent mechanism responsible for bone formation
functions during mechanical loading, not after (Chow et al., 1998; Li
et al., 2002). Collectively, animal studies suggest prostaglandin synthe-
sis mechanically induced by COX-2 expression after loading does not
contribute to bone formation. Ingesting ibuprofen after resistance train-
ing would therefore allow the prostanoid-dependent mechanism dur-
ing loading to stimulate bone formation while blunting the increased
production of harmful prostaglandins following exercise that may con-
tribute to chronic inﬂammation. Our results, however, do not support
either a detrimental or beneﬁcial effect of ibuprofen supplementation
after exercise loading of bone.
Ibuprofen and exercise were neither additive nor effective for in-
creasing lean tissue mass. These ﬁndings are in support of prior studies
showing no signiﬁcant beneﬁt to lean tissue mass when supplementing
resistance training with 400 mg (versus placebo) of ibuprofen in youn-
ger or older women during resistance training programs (Kohrt et al.,
2010; Candow et al., 2013; Krentz et al., 2008); however, potential ex-
ists for higher-ibuprofen dose to increase muscle mass in older adults
who are participating in a resistance training program. It wasdemonstrated that 1200 mg of ibuprofen following resistance training
increased lean tissue mass in older adults (Trappe et al., 2011). Perhaps
the lack of improvement in lean tissue mass in our study and others
(Kohrt et al., 2010; Candow et al., 2013; Krentz et al., 2008) is due to a
lower dose (i.e. 400 mg versus 1200 mg). The low-dose of ibuprofen
used, while safe and effective for increasing hip aBMD in premenopaus-
al women (Kohrt et al., 2010), may not have been sufﬁcient enough to
counteract the resistance-training induced inﬂammatory response and
catabolism which occurs in postmenopausal women. While the inﬂam-
matory and catabolic effects of exercisemay lead to greatermuscle pro-
tein synthesis and are thus beneﬁcial in younger adults, this may not be
the case with aging adults. While it is well accepted that resistance
training prevents sarcopenia, evidence from animal studies suggest ibu-
profen may be of beneﬁt as well (Greig et al., 2009). A daily dosage of
30 mg kg−1 prevented muscle wasting in old (i.e. 20 month old) rats;
again this would translate to a much higher dose than used in our
study and others if implemented in humans (e.g. 2220 mg for a 70 kg
adult) (Rieu et al., 2009).
The effects of pro-inﬂammatory cytokines at the cellular and meta-
bolic level should theoretically manifest as a measurable loss of muscle
mass and strength and bone density and strength. There is dysregula-
tion of inﬂammatory cytokines with age leading to over-production of
pro-inﬂammatory cytokines such as interleukin-6 (IL-6) and tumor ne-
crosis factor (TNF-α) (Degens, 2010). Precursors for these inﬂammatory
cytokines include prostaglandins (i.e. PGE1 and PGE2)which are synthe-
sized through the cyclooxygenase pathway from arachidonic acidmedi-
ated by the enzymes cyclooxygenase-1 and 2 (COX-1; COX-2) (Degens,
2010; Lopez-Otın et al., 2013). In our study, inﬂammation may have
been reduced at the cellular and metabolic level and simply did not
manifest into measurable changes at the tissue level. One could include
measurements of the cellular and metabolic level over a shorter dura-
tion if a longer duration study is not feasible. However, an optimal inter-
vention might require a longer duration, perhaps over 2 years, to allow
changes to manifest at the tissue level.
The 4-group design of our study allowed the assessment of the inter-
action between ibuprofen and exercise training. An additional strength
of our studywas the high compliance in all intervention arms. However,
our study had a number of limitations. Potential participants with high
fracture risk were excluded via CAROC method, limiting generalizabili-
ty. Ward's region aBMD was among ﬁve femoral neck measures
assessed. We did not make adjustments for multiple comparisons;
therefore, our Ward's region ﬁndings could be by chance (i.e. statistical
error). Further, Ward's region is limited via overestimation of osteopo-
rosis and should not be used in diagnosis (El Maghraoui and Roux,
2008). Our study was most likely underpowered to detect statistically
signiﬁcant differences between groups for primary variables. To detect
≥1% difference in aBMD of clinically relevant sites with 90% power
each group would require approximately 40 per-protocol participants
(2 sided, p ≤ 0.05); thus, to account for ~20% attrition, a sample size of
103W.R.D. Duff et al. / Bone Reports 5 (2016) 96–103200 is required (Jankowski et al., 2015). Future research efforts should
employ a similar study design with four recommended alterations:
1) increase to a daily dosage of 400 mg of ibuprofen, 2) alter the timing
of the ibuprofen supplementation, so that supplementation does not
occur within close proximity to the exercise, 3) lengthen the duration
of the intervention, and 4) increase sample size to 200.
5. Conclusion
Ibuprofen supplementation immediately after resistance training
did not have an additive effect on bone or muscle mass in postmeno-
pausal womenwith low to moderate fracture risk. In contrast, our ﬁnd-
ings suggested that ibuprofen as administered by itself may have some
beneﬁt atWard's region of the proximal femur. The timing and the dose
of the ibuprofen may be important.
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